oV with an inhibitor  3X5  240 µM  [27]
4OVZ  CoV PLPro complexed with inhibitor  P85  490 nM  [31]
3MJ5  SARS-CoV PLPro complexed with inhibitor  GRM  320 nM  [32]
2FE8  SARS-CoV PLPro  -  -  [33]
1UK4  SARS-CoV 3CLPro and its interactions with an inhibitor  Substrate analog hexapeptidyl CMK inhibitor  IC50 ca. 2 mM  [34]
1UJ1, 1UK3, 1UK2  SARS-CoV M-pro, apo-enzyme at different pH  -  -  [34]
3VB6  SARS-CoV 3CLPro in complex with C6Z  C6Z  39 µM  [35]
3VB5  SARS